Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELSTAR-2: Treatment of Electroencephalographic Status Epilepticus After Cardiopulmonary Resuscitation
2024-516068-27-01Phase 3Authorised
- Sponsor
- University of Twente
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial of midazolam, levetiracetam, esketamine, propofol, diazepam and 3 more in status epilepticus (SE), cardiac arrest (SCA) and hypoxic-ischemic encephalopathy (HIE) (2 arms), sponsored by University of Twente. Primary endpoint: Functional recovery at 6 months. Planned start Mar 2025; status: authorised.
02
Drugs
midazolamlevetiracetamesketaminepropofoldiazepam
03
Conditions
status epilepticus (SE)cardiac arrest (SCA)hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on 2024-516068-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516068-27-01.